ARTICLE | Clinical News
CP461: Began Phase I trial
May 10, 1999 7:00 AM UTC
Cell Pathways Inc. (CLPA), Horsham, Penn. Product: CP461 Business: Cancer Therapeutic category: Apoptosis Target: cGMP-PDE Description: Selective inducer of apoptosis Indication: Treat cancer Status: ...